Zhongxing Liao MD

Radiation Oncology•Houston, TX

Professor of Radiation Oncology, University Tex Houston

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas M D Anderson Cancer CenterResidency, Radiation Oncology, 1995 - 1999
University of Kansas (Wichita)Internship, Internal Medicine, 1994 - 1995
Hunan Medical UniversityClass of 1982

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2026
MS State Medical License 2024 - 2026
OK State Medical License 2020 - 2026
TX State Medical License 1998 - 2026
WA State Medical License 2024 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
TN State Medical License 2024 - 2025
American Board of Radiology Radiation Oncology
Join now to see all

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Thermal Signature of Patients Undergoing Radiation Therapy Start of enrollment: 2007 Jul 01
Withdrawn
3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy Start of enrollment: 2007 Aug 21
Completed
Phase 2
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer Start of enrollment: 2008 Jan 25
Terminated
Phase 1
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence Start of enrollment: 2009 Jun 01
Completed
Phase 2
A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil Start of enrollment: 2011 Jul 01
Completed
Not Applicable
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer Start of enrollment: 2012 Sep 17
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Phase II Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2008 Jan 01
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Start of enrollment: 2014 Feb 03
ACTIVE_NOT_RECRUITING
PHASE3
Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation Start of enrollment: 2021 Jul 05
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Deep Learning-Based Cardiac Chamber Segmentation in Magnetic Resonance-Guided Adaptive Radiation Therapy.
Xinru Chen, Yao Ding, Julius Weng, Carol C Wu, Yao Zhao
Advances in Radiation Oncology. 2025-09-01
2 citations
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.
Everett J Moding, Mohammad Shahrokh Esfahani, Cheng Jin, Angela B Hui, Barzin Y Nabet
Cancer Discovery. 2025-08-04
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC.
Maliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li
Nature Communications. 2025-07-24

Journal Articles

The Utility of Quantitative Ct Radiomics Features for Improved Prediction of Radiation Pneumonitis
Zhongxing Liao, MD, Medical Physics
Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?☆
Zhongxing Liao, Saumil J Gandhi, Steven H Lin, ScienceDirect

Authored Content

Cost Analysis of PET/CT vs. CT as Surveillance for Stage III Non-Small Cell Lung Cancer After Definitive Radiation TherapyMarch 2018
Out of the Darkness and into the Light: New Strategies for Improving Treatments for Locally Advanced Non-Small Cell Lung CancerFebruary 2018

Press Mentions

Nanobiotix Announces First Data from the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients with Locally Advanced NSCLCMarch 27th, 2025
Leading Radiation Oncologist Zhongxing Liao, MD, Is to Be Recognized as a 2016 Top Doctor in Houston, TexasJanuary 9th, 2017

Grant Support

Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patientsUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026